13.50
-0.24(-1.75%)
Currency In USD
Previous Close | 13.74 |
Open | 13.63 |
Day High | 13.65 |
Day Low | 13.44 |
52-Week High | 29.3 |
52-Week Low | 12.87 |
Volume | 596,132 |
Average Volume | 923,085 |
Market Cap | 1.23B |
PE | -10.55 |
EPS | -1.28 |
Moving Average 50 Days | 17.42 |
Moving Average 200 Days | 22.62 |
Change | -0.24 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $380.71 as of December 27, 2024 at a share price of $13.5. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $504.11 as of December 27, 2024 at a share price of $13.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
GlobeNewswire Inc.
Dec 19, 2024 9:15 PM GMT
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick ModelSALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and gen
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
GlobeNewswire Inc.
Dec 10, 2024 11:26 PM GMT
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
GlobeNewswire Inc.
Dec 10, 2024 9:05 PM GMT
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Boar